Revenue: As of FY2025 Q2, the actual value is USD 257.82 K.EPS: As of FY2025 Q2, the actual value is USD -1.25.<h3>Segment Revenue</h3><ul><li>Product Revenues – net of Discounts and Rebates: $100,932 for the three months ended June 30, 2025, compared to $124,972 for the same period in 2024, representing a decrease of 19.24%.</li><li>Research Revenues: $206,939 for the three months ended June 30, 2025, compared to $728 for the same period in 2024, representing a significant increase due to new contracts.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: $50,881 for the three months ended June 30, 2025, compared to $35,408 for the same period in 2024, an increase of 43.70%.</li><li>Total Operating Expenses: $1,862,648 for the three months ended June 30, 2025, compared to $4,224,886 for the same period in 2024, a decrease of 55.91%.</li><li>Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc.: - $1,733,726 for the three months ended June 30, 2025, compared to - $4,172,755 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $3,047,494 for the six months ended June 30, 2025, compared to - $2,328,650 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $1,650,834 for the six months ended June 30, 2025, compared to - $140,373 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $1,696,899 for the six months ended June 30, 2025, compared to $1,902,426 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue developing and commercializing new therapies for infectious diseases, with a focus on expanding the market for Arakoda and other pipeline products.</li><li>Non-Core Business: The company is exploring additional revenue streams through research contracts and partnerships, such as the USAMMDA contract for Arakoda supply chain upgrade support.</li><li>Priority: The company aims to achieve profitability by raising additional capital and increasing sales of its marketed product, Arakoda, while managing operating expenses.</li></ul>

60 Degrees Pharmaceuticals | 10-Q: FY2025 Q2 Revenue: USD 257.82 K